Jun 18, 2020
ARO Volcani Centre in Collaboration with Rabin Medical Centre, and MedC Biopharma Corporation, Announce the publication of its Research in a Peer-Reviewed Scientific Journal - Oncotarget.
Apr 30, 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Apr 06, 2020
Soligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma
Feb 18, 2020
Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions
Dec 08, 2019
Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies
Nov 19, 2019
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Oct 31, 2019
Mallinckrodt Announces UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in Adults
Oct 24, 2019
Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition
Aug 13, 2019
Moleculin Announces Completion of Lymphoma Trial Enrollment
Jun 03, 2019
Kyowa Kirin Presents Post-Hoc Analysis of Pivotal Trial for Poteligeo® (mogamulizumab-kpkc)
Mar 19, 2019
Moleculin Announces First Patients Enrolled in Lymphoma Clinical Trial
Mar 04, 2019
Mallinckrodt Presents New Data on Real-World Resource Utilization Associated with Continuation of Systemic Treatment among Patients with Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting
Dec 17, 2018
Volcani Center Announces Significant Breakthroughs in CTCL Skin Cancer Cannabis Treatment Development in Cooperation With MedC Biopharma Corporation of Canada
Dec 03, 2018
Kyowa Kirin Presents Additional Analyses of MAVORIC Trial
Aug 22, 2018
Soligenix Receives US Patent for Improved Production of Synthetic Hypericin
Aug 10, 2018
Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab Published in Lancet Oncology
Aug 08, 2018
Soligenix Announces Recent Accomplishments And Second Quarter 2018 Financial Results
Aug 08, 2018
Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome
Jun 18, 2018
Continued Discussions With FDA on Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
Jun 04, 2018
Kyowa Kirin Presents New Data for Mogamulizumab from Its Lead Program in Cutaneous T-cell Lymphoma (CTCL) at ASCO